Stargardt disease (STGD) is a monogenic disease characterized by retinal dystrophy and macular degeneration that results in progressive loss of vision. In contrast to many other forms of macular degeneration or retinal dystrophy, STGD typically strikes patients in early adulthood. Despite the severity of the disease and the tremendous burden it inflicts on patients, there are no therapies approved to treat STGD. Although VEGF inhibitors (Avastin, Eylea, Lucentis) are prescribed off-label on rare occasions, there is no clinical evidence from prospective trials that the agents are effective in STGD. However, several therapies with novel mechanisms of action are in development to treat STGD and, if efficacious, stand to capitalize on the immense unmet need for effective therapies in this space.
Executive Insights provides indication-specific market intelligence with world-class epidemiology, keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.